Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913061 | 0.85 | C5AR1 (0.38) | TP53POLBLMNAMAPTALDH1A1 | |
| SCHEMBL5135107 | 0.77 | C5AR1 (0.47) | TP53POLBLMNAMAPTALDH1A1 | |
| SCHEMBL5138076 | 0.77 | AGTR1 (0.36) | — | |
| SCHEMBL5137318 | 0.76 | PIN1 (0.36) | ALDH1A1HTT | |
| SCHEMBL5136239 | 0.74 | L3MBTL1 (0.34) | LMNAALDH1A1HTT | |
| SCHEMBL648864 | 0.74 | C5AR1 (0.41) | ALDH1A1HTT | |
| SCHEMBL5136020 | 0.74 | PTGER4 (0.41) | ALDH1A1 | |
| SCHEMBL5135264 | 0.73 | ALDH1A1 (0.31) | ALDH1A1HTT | |
| SCHEMBL1913060 | 0.72 | C5AR1 (0.56) | POLBLMNAMAPTALDH1A1HTT | |
| SCHEMBL5136195 | 0.72 | CA1 (0.33) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |